tbuckley/cabot-search huggingface dataset:
Medical Organization.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mind: A Social Phenomenon, Illustrated by the Growth of Medical Knowledge
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Back Pain
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Development or worsening of esophageal varices in patients with cirrhosis after DAA-induced HCV clearance
Authors: Vincenza Calvaruso, Massimo Licata, Fabio Simone, Lorenza Di Marco, Luigi Cusimano, Graziano Troina, Luciano Crapanzano, Gerlando Gibilaro, Salvatore Petta, Antonio Craxi, Vito Di Marco
Journal: Journal of Hepatology (2020)
Live attenuated rubella virus vaccines prepared in duck embryo cell culture. I. Development and clinical testing
Authors: E. B. Buynak
Journal: JAMA (1968)

Merck strain rubella virus and Meyer-Parkman monkey kidney attenuated HPV-77 virus were prepared at various levels of attenuation for investigative use in humans and animals. The vaccines were produced in duck embryo cell culture and represented a spectrum which ranged from underattenuation, causing communicable mild rubella, to overattenuation with apparent nonexcretion and inadequate immunization. Merck strain rubella virus at attenuation level B, or possibly C, and Meyer-Parkman HPV-77 virus in fifth passage in duck embryo cell culture appear to present the attributes of an effective noncontagious vaccine. The antibody, produced in children after administration of level C vaccine, persisted undiminished for at least one year. Duck embryo cell culture appeared to be an attractive material for preparing vaccine because it was of a nonmammalian source and because of the relative freedom of ducks from disease.
PP43. THE EFFICACY AND MECHANISM OF THERAPEUTIC STIMULATING ELECTRODES IN GLIOBLASTOMA MULTIFORME
Authors: Mr Joshua Branter, Dr Maria de los Angeles Estevez-Cebrero, Prof Richard Grundy, Mr Surajit Basu, Dr Stuart Smith
Journal: Neuro-Oncology (2017)

INTRODUCTION: In light of the outcomes of the Phase III trials of Tumour Treating Fields (TTFields) in both primary and recurrent adult Glioblastoma multiforme (GBM), a new treatment modality has emerged. TTFields are low intensity (1-3V/cm), intermediate frequency (200kHz) alternating electric fields delivered throughout the brain via external attached electrodes. Overall, TTFields have been found to benefit patients when administered as both a monotherapy and combinational therapy with Temozolomide. TTFields efficacy is largely dependent upon patient compliance with the external power and delivery systems, while effective voltage intensity is limited by resistance from the skin, subcutaneous tissues and skull. Here we present investigations into the application of deep brain stimulation (DBS) electrodes as a novel delivery method of therapeutic electromagnetic fields to high grade brain tumours as an internalised system. METHODS: Medtronic DBS electrodes were inserted into standard cell culture flasks and to deliver electric fields over a multitude of voltages and frequencies to a panel of primary, adult and paediatric GBM cell lines. Cell viability was analysed with Presto Blue assay and gene expression was assessed with quantitative RT-PCR. Cell cycle analysis was undertaken through FACS. The synergistic effects of electric fields and mitosis-specific targeting agents was also assessed. RESULTS: DBS electric fields negatively effects cell viability over a range of GBM cell lines (commercial and primary low passage) in a voltage-dependent manner. Cell viability was reduced by up to 70% and 74% in voltage-dependent manner over the range of voltages (0V to 10V) for 7 days - U87 cells (Two-way ANOVA, p=0.0014) and SF188 cells (Two-way ANOVA, p=0.0001). Cell counts were undertaken of treated U87 and SF188 flasks with a reduction of 93% and 82% respectively, with a greatest reduction in proportion of cells within close proximity to the DBS electrode. We examine synergistic effects with mitotic inhibitor agents. CONCLUSIONS: Implantable DBS electrodes have potential as a novel therapeutic strategy for the treatment of brain tumours. Electric fields delivered through DBS electrodes demonstrate anti-proliferative effects on GBM cell lines in a dose-dependent manner. This effect is actualised at frequencies substantially lower than those utilised by NovoTTF therapy and may represent a different treatment paradigm e.g. interference with ion channels. Impact: Proof-of-concept of electric fields treatment has been demonstrated by the OptuneTM system, however limitations of patient adherence persists, but implantable DBS electrodes may address these issues.
Phase I/II study of sunitinib (SU) in combination with metronomic dosing of cyclophosphamide (C) and methotrexate (M) in patients (pts) with metastatic breast cancer (MBC).
Authors: A. J. Chien, J. Aicardi, M. E. Melisko, A. Goga, M. M. Moasser, J. W. Park, P. N. Munster, H. S. Rugo
Journal: Journal of Clinical Oncology (2010)

1067 Background: Metronomic chemotherapy has demonstrated antitumor activity in preclinical and clinical studies in a number of solid tumors. The effects of metronomic chemotherapy appear to be enhanced when combined with targeted antiangiogenic agents in vivo, and with bevacizumab in women with MBC. We conducted a phase 1/2 clinical study of daily SU, a potent oral multi- targeted tyrosine kinase inhibitor, in combination with metronomic dosing of oral C and M in patients with MBC. Methods: Pts were treated with a 2-week course of SU monotherapy followed by combination treatment consisting of daily SU, C (50 mg/day), and M (2.5 mg/bid on days 1-2 each week). Eligibility included MBC with any number of prior therapies. In phase 1, SU was dose-escalated in 3 cohorts (12.5, 25, and 37.5 mg/day). In phase 2, all patients received SU 37.5 mg/day in combination with CM. Serial blood work for circulating tumor cells (CTCs) and circulating endothelial cells (CECs) was collected for all patients. Results: A total of 28 pts have been enrolled to date (21 in phase 1; 7 in phase 2). The most common adverse events in phase 1 were grade 3 neutropenia and thrombocytopenia. Other grade 3 toxicities included liver function abnormalities, mucositis, and foot pain. Dose-limiting toxicity at 37.5 mg/day consisted of one grade 4 thrombocytopenia. Of 7 pts enrolled in phase 2, two discontinued treatment due to unacceptable toxicity (treatment delay due to grade 3 neutropenia and thrombocytopenia). Two pts required dose-reductions (grade 3 foot pain; and grade 3 neutropenia and thrombocytopenia). Of the 19 pts receiving either SU 25 mg/day or 37.5 mg/day that were evaluable for response, one (5%) had a confirmed partial response, 9 (47%) had stable disease (3 for greater than 11 months), and 9 (47%) had progressive disease at first restaging. Conclusions: Continuous daily SU 37.5 mg/day in combination with metronomic dosing of CM is associated with hematologic toxicity requiring dose reduction in heavily pretreated pts with MBC. Preliminary data indicate significant clinical activity despite extensive prior therapy. Additional patients will be enrolled at SU 25 mg/d with CM. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer Pfizer
Ex Vivo Antisense Oligonucleotides to Proliferating Cell Nuclear Antigen and Cdc2 Kinase Inhibit Graft Coronary Artery Disease
Authors: Douglas N. Miniati, E. Grant Hoyt, Brian T. Feeley, Robert S. Poston, Robert C. Robbins
Journal: Circulation (2000)

Background —The long-term success of cardiac transplantation is limited by graft coronary artery disease (GCAD). Antisense oligonucleotides (ASs) to proliferating cell nuclear antigen (PCNA) and Cdc2 kinase (Cdc2 k) can arrest cell cycle progression and inhibit neointimal hyperplasia. Transforming growth factor-β 1 (TGF-β 1 ) has been implicated in vascular smooth muscle cell (VSMC) activation. The role of TGF-β 1 in GCAD remains unclear. We hypothesized that ASs to PCNA and Cdc2 k would inhibit VSMC proliferation and GCAD. Methods and Results —In vitro VSMC proliferation was determined after pretreatment with AS solution or medium alone followed by angiotensin II stimulation. PVG-to-ACI rat heterotopic cardiac transplantation procedures were performed after ex vivo pressure-mediated transfection of ASs to PCNA and Cdc2k or saline alone. At postoperative days 30, 60, and 90, allografts were assessed for GCAD, percent neointimal macrophages and VSMCs, and TGF-β 1 activity. AS pretreatment significantly attenuated VSMC proliferation. At postoperative day 90, percent affected arteries, percent occlusion, and intima-media ratio demonstrated severe GCAD in saline-treated allografts, whereas these parameters were significantly lower in AS-treated allografts. Percent neointimal macrophages and VSMCs was reduced in AS-treated allografts. TGF-β 1 activity was increased in saline compared with AS-treated allografts and nontransplanted heart controls. Conclusions —ASs to PCNA and Cdc2 k inhibit VSMC proliferation in vitro and reduce GCAD, percent neointimal VSMCs and macrophages, and TGF-β 1 activity in vivo. TGF-β 1 may play a “response to injury” role in the development of GCAD. The prevention of GCAD via AS inhibition of cell cycle regulatory genes before reperfusion may offer a useful clinical alternative to current therapeutic strategies.
Tetanus toxoid as an antigen for delayed cutaneous hypersensitivity
Authors: J. C. Delafuente
Journal: JAMA (1983)

We studied the usefulness of tetanus toxoid (TT) as a skin test antigen in assessing cellular immune function. Hospitalized patients were skin tested with four antigens, and the response rates between these antigens were compared.<i>Candida</i>and mumps antigens resulted in significantly more positive responses than did TT or PPD. The response rate to the TT significantly declined in older patients, suggesting these persons may not be adequately immunized against tetanus. We found TT is not as useful as<i>Candida</i>or mumps antigens in the evaluation of cellular immune function in a hospitalized population but it may have some usefulness in the evaluation of anergy. Negative skin test results may convert to positive after patients receive an immunizing dose of TT, as shown by our data. In addition, there were several patients with a positive response to TT and negative responses to the other common skin test antigens. (<i>JAMA</i>1983;249:3209-3211)
Oto-Rhino-Laryngology for the Student and Practitioner.
Journal: JAMA (1923)

The first edition of this work was spoken of in these columns as the ideal textbook for practitioners and students, because of its essentially practical character. In the present volume none of this value is lost, and numerous additions have been made. The author's minuteness of detail, his brief, sensible descriptions, the clever arrangement of his text, and, above all, his sane instructions under the headings What to do and What to avoid give to the student a broad view of this field, and to the practitioner a safe working basis in the absence of the specialist.
Intraoperative Diagnosis and Management of Patent Foramen Ovale—Reply
Authors: Stephen A. Hart
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Problem Doctors: Is There a System-Level Solution?
Authors: Martin T. Donohoe
Journal: Annals of Internal Medicine (2006)

Letters6 June 2006Problem Doctors: Is There a System-Level Solution?Martin T. Donohoe, MDMartin T. Donohoe, MDFrom Portland State University, Portland, OR 97207-0751.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-144-11-200606060-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The explosive growth of preemployment and random, not-for-cause drug testing in industry and health care raises ethical, legal, and policy questions (1). Such growth has been fueled by popular misconceptions surrounding substance use and abuse, junk science, and business interests (Institute for a Drug-Free Workplace, pharmaceutical firms, and drug-testing companies) and by the public relations campaigns of a multibillion-dollar industry whose entrepreneurial interest lies in magnifying the severity of drug-related problems in the workplace and extolling the benefits of drug testing as a solution (2).Preemployment and random drug testing to find one otherwise hidden drug abuser ...References1. Donohoe M. Urine trouble: practical, legal, and ethical issues surrounding mandated drug testing of physicians. J Clin Ethics. 2005;16:85-96. [PMID: 15915849] MedlineGoogle Scholar2. Lundberg GD. Mandatory unindicated urine drug screening: still chemical McCarthyism. JAMA. 1986;256:3003-5. [PMID: 3773220] CrossrefMedlineGoogle Scholar3. Matlby LL. Drug testing: a bad investment. 1999. Accessed at http://www.aclu.org/news/1999/n090199a.html on 18 May 2000. Google Scholar4. Normand J. Under the Influence? Drugs and the American Workforce. Washington, DC: National Academy Pr; 1994. Google Scholar5. Montoya ID, Carlson JW, Richard AJ. An analysis of drug abuse policies in teaching hospitals. J Behav Health Serv Res. 1999;26:28-38. [PMID: 10069139] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Portland State University, Portland, OR 97207-0751.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoProblem Doctors: Is There a System-Level Solution? Lucian L. Leape and John A. Fromson Problem Doctors: Is There a System-Level Solution? David R. Gifford , Robert S. Crausman , and Bruce W. Mcintyre Problem Doctors: Is There a System-Level Solution? Lucian L. Leape and John A. Fromson Problem Doctors: Is There a System-Level Solution? Duncan M. Kuhn Problem Doctors: Is There a System-Level Solution? Mark S. Gold and Kimberly Frost-Pineda Metrics 6 June 2006Volume 144, Issue 11Page: 862KeywordsAddictsDrug abuseDrug informationDrug policyDrugsResidencySafetySleep deprivationSubstance abuseVision ePublished: 6 June 2006 Issue Published: 6 June 2006 Copyright & PermissionsCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Treatment of verrucae with smallpox vaccine
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ORI Begins Investigation Related to NSABP Of Possible Misconduct in Science
Journal: JNCI Journal of the National Cancer Institute (1994)

ORI Begins Investigation Related to NSABP Of Possible Misconduct in Science Get access JNCI: Journal of the National Cancer Institute, Volume 86, Issue 22, 16 November 1994, Page 1674, https://doi.org/10.1093/jnci/86.22.1674 Published: 16 November 1994
Males in Rural Bangladeshi Communities Are More Susceptible to Chronic Arsenic Poisoning Than Females: Analyses Based on Urinary Arsenic
Authors: Chiho Watanabe, Tsukasa Inaoka, Takefumi Kadono, Megumi Nagano, Satoshi Nakamura, Kayo Ushijima, Nobuko Murayama, Kaori Miyazaki, Ryutaro Ohtsuka
Journal: Environmental Health Perspectives (2001)

Spot urine samples were collected from the inhabitants of two rural communities in northwestern Bangladesh. We compared arsenic levels in the urine samples ([As](u); n = 346) with those in water from tube wells ([As](tw); range < 1-535 microg/L; n = 86) on an individual basis. The small variation of [As](u) within subjects and highly positive correlation with [As](tw) indicate that [As](u) is a useful indicator of exposure. Analyses of [As](u) showed that creatinine correction was necessary, that [As](u) only reflected recent exposure, and that there were substantial interindividual differences for a given [As](tw) level. To evaluate the toxic effects of arsenic exposure, we constructed a system for rating skin manifestations, which revealed distinct sex-related differences. Comparison of males and females in the same households confirmed that skin manifestations were more severe in the males, and in the males of one community a dose-response relationship between [As](u) and the degree of skin manifestation was evident. The results of this study indicate that [As](u) in spot urine samples can be used as an exposure indicator for As. They suggest that there might be sex-related, and perhaps community-related, differences in the relationship between [As](u) and skin manifestations, although several confounding factors, including sunlight exposure and smoking habits, might contribute to the observed sex difference. The existence of such differences should be further confirmed and examined in other populations to identify the subpopulations sensitive to chronic arsenic toxicity.
Erratum
Journal: Neuro-Oncology (2009)

Additional criteria apply.Please refer to protocol 14379-201 for full inclusion and exclusion criteria.† Patients can participate if they had some skin cancers, superficial bladder cancer (cancer that was only on the surface of the lining of the bladder), or carcinoma in situ (cancer that had not spread) of the cervix or breast that had been cured.